Connective tissue growth factor reacts as an IL - World Journal of ...

More documents

Recommendations

Info

A B IL-6 (35 μg/L) - - + + + + - sgp80 (1 mg/L) - - - - + + + sgp130 (2 mg/L) - + - + - + - CTGF/β-actin (%) α1-AT/β-actin (%) C CRP (mg/L) CTGF α1-AT β-actin 120 80 40 0 200 150 100 50 0 0.21 0.18 0.15 Co Co Co b gp130 b gp130 gp130 IL-6 IL-6 WJG|www.wjgnet.com a IL-6 + gp130 IL-6 IL-6 + gp130 IL-6 + gp130 IL-6 + gp80 IL-6 + gp80 + gp130 IL-6 + gp80 IL-6 + gp80 + gp130 IL-6 + gp80 IL-6 + gp80 + gp130 gp80 gp80 gp80 Gressner OA et al . CTGF is a negative acute phase protein CTGF/β-actin (%) α1-AT/β-actin (%) D CRP (mg/L) IL-6 (35 μg/L) - - + + + + - sgp80 (1 mg/L) - - - - + + + sgp130 (2 mg/L) - + - + - + - CTGF α1-AT β-actin 120 80 40 0 150 100 50 0 0.8 0.6 0.4 0.2 Co Co Co b gp130 a gp130 gp130 IL-6 IL-6 IL-6 + gp130 IL-6 IL-6 + gp130 IL-6 + gp80 IL-6 + gp80 + gp130 IL-6 + gp80 IL-6 + gp80 + gp130 gp80 gp80 157 January 14, 2011|Volume 17|Issue 2| a IL-6 + gp130 IL-6 + gp80 IL-6 + gp80 + gp130 Figure 3 Soluble gp80 receptor enhances the inhibitory effect of interleukin-6 on hepatocellular CYR61/CTGF/NOV 2/connective tissue growth factor expression in primary human hepatocytes. A: Western blottings of CYR61/CTGF/NOV (CCN) 2/Connective tissue growth factor (CTGF) and α1-AT of primary human hepatocytes cultured under serum-free conditions for 24 h and stimulated with rh interleukin (rhIL)-6 (35 μg/L), soluble gp80 receptor (sgp80, 1 mg/L) and soluble gp130 receptor (sgp130, 2 mg/L) or a complex of both. Cells were harvested after 24 h. β-actin served as loading control. Blots were quantified relative to β-actin using the Lumi Imager System. Representative blots are shown. a P < 0.005, b P < 0.0001 vs untreated or IL-6 treated control; B: Primary human hepatocytes were cultured and stimulated as described in (A). Cells were harvested after 48 h. β-actin served as loading control. Blots were quantified as described in (A). Representative blots are shown. a P < 0.005, b P < 0.0001 vs untreated or IL-6 treated control; C, D: Ultrasensitive C-reactive Protein as determined using a particle enhanced ultra sensitive assay on the Siemens BN2 nephelometer in supernatants from primary human hepatocytes cultures harvested after 24 h (C) and 48 h (D). The baseline indicates the lower detection limit of the assay at 0.15 mg/L. gp80
A Gressner OA et al . CTGF is a negative acute phase protein py-STAT3/STAT3/β-actin (x-fold increase) IL-6 (10 μg/L) - + + - 10 Edelfosine - - + + IL-6 (10 μg/L) + - + + - IL-6 (10 μg/L) - + - + - + - + B CTGF/β-actin (%) PD98059 - - + + - - - - 200 100 0 8 6 4 2 0 Co a IL-6 PD PD + IL-6 WJG|www.wjgnet.com UO UO + IL-6 a Co IL-6 PDTC (25 μmol/L) PDTC (50 μmol/L) PDTC (100 μmol/L) PDTC (25 μmol/L) + IL-6 PDTC (50 μmol/L) + IL-6 PDTC (100 μmol/L) + IL-6 SB SB + IL-6 IL-6 (10 μg/L) - + - - - + + + PDTC (μmol/L) - - 25 50 100 25 50 100 py-STAT3 STAT3 β-actin UO126 - - - - + + - - SB203580 - - - - - - + + CTGF β-actin CTGF β-actin CTGF/β-actin (%) 120 80 40 0 a Co IL-6 Edelfosine + IL-6 Edelfosine C PDTC (μmol/L) - 50 50 100 - D CTGF β-actin CTGF/β-actin (%) 120 80 40 0 b IL-6 PDTC (50 μmol/L) 158 January 14, 2011|Volume 17|Issue 2| b PDTC (50 μmol/L) + IL-6 PDTC (100 μmol/L) + IL-6 IL-6 (20 μg/L) - - - + + + PY*LKTK (μmol/L) - 25 100 - 25 100 py-STAT3 E STAT3 β-actin py-STAT3/STAT3/ β-actin (%) IL-6 (20 μg/L) - - - + + + PY*LKTK (μmol/L) - 25 100 - 25 100 CTGF β-actin CTGF/β-actin (%) 250 200 150 100 50 0 120 150 100 Co PY*LKTK (25 μmol/L) 50 0 a Co PY*LKTK (25 μmol/L) b PY*LKTK (100 μmol/L) b PY*LKTK (100 μmol/L) b IL-6 (20 μmol/L) PY*LKTK (25 μmol/L) + IL-6 IL-6 (20 μmol/L) b PY*LKTK (25 μmol/L) + IL-6 Co PY*LKTK (100 μmol/L) + IL-6 PY*LKTK (100 μmol/L) + IL-6
Page 1 and 2: World Journal of Gastroenterology W
Page 3 and 4: Robert JL Fraser, Daw Park Jacob Ge
Page 5 and 6: Italy Donato F Altomare, Bari Piero
Page 7 and 8: Fernando Azpiroz, Barcelona Ramon B
Page 9 and 10: S Contents EDITORIAL TOPIC HIGHLIGH
Page 11 and 12: Contents APPENDIX FLYLEAF EDITORS F
Page 13 and 14: Ouyang D et al . Pancreatic endocri
Page 19 and 20: Online Submissions: http://www.wjgn
Page 21 and 22: Diamantis G et al . Quality of life
Page 27: Gressner OA et al . CTGF is a negat
Page 30 and 31: A B CTGF luciferase activity (lcps)
Page 34 and 35: F mt distal mt proximal wt 9 8 7 6
Page 36 and 37: + CTGF TGF-β IL-6 + - + an acute p
Page 38 and 39: 2007; 46: 295-303 21 Karger A, Fitz
Page 40 and 41: 2011; 17(2): 164-173 Available from
Page 43 and 44: A B C -80 mV E Relative expression
Page 45: A C Park KS et al . Serotonergic si
Page 48 and 49: 19 Li T, Weng SG, Leng XS, Peng JR,
Page 50 and 51: Recurrent GB cancer has been report
Page 52 and 53: Table 2 Surgical procedures for muc
Page 54 and 55: esection of the common bile duct sh
Page 58 and 59: NaF, 1% Triton X-100, and 0.5 mmol/
Page 60 and 61: A Oxaliplatin LY294002 C Oxaliplati
Page 62 and 63: A Tumor volume (mm 3 ) C 5000 4000
Page 64 and 65: 2 Hundahl SA, Phillips JL, Menck HR
Page 68 and 69: the typical MII pattern of GOR. Thi
Page 70 and 71: emptying, that arises from the anch
Page 74 and 75: medical treatment, age at diagnosis
Page 76 and 77: Table 3 Odds ratio for the studied
Page 78 and 79: Table 6 Published associations betw
Page 80 and 81: anti-CBir1 and ASCA, and show reduc
Page 85:
Faria GR et al . Acute diverticulit
Page 88 and 89:
Online Submissions: http://www.wjgn
Page 90 and 91:
Changes in flow vs T0 (%) Changes i
Page 93 and 94:
Hanssen SJ et al . Hemolysis and in
Page 95 and 96:
Kuiper P et al . Angiogenic markers
Page 97 and 98:
Kuiper P et al . Angiogenic markers
Page 99 and 100:
A Comulative survival C Comulative
Page 101 and 102:
Page 103 and 104:
Nishida U et al . ASA induced small
Page 105 and 106:
Nishida U et al . ASA induced small
Page 107 and 108:
Okano K et al . FDG-PET small pancr
Page 109 and 110:
Okano K et al . FDG-PET small pancr
Page 111:
Page 114 and 115:
Table 3 Prevalence of IgG anti-hepa
Page 116:
1005-1022 24 Hendrickx G, Van Herck
Page 123:
Choi YS et al . Alternative cleansi
Page 129 and 130:
Page 131 and 132:
Plasma endotoxin (EU/L) Small intes
Page 133 and 134:
Zhang Y et al . Effects of penehycl
Page 135:
Page 139:
C Review: CYP1A1 Ile462Val polymorp
Page 142:
Page 145 and 146:
Kim SO et al . Sorafenib-induced sp
Page 147 and 148:
Sahebkar A. Ginger as a natural sup
Page 149 and 150:
Page 151 and 152:
Instructions to authors Indexed and
Page 153 and 154:
Instructions to authors uniform leg
Page 155:
Instructions to authors Language ev
show all

Connective tissue growth factor reacts as an IL - World Journal of ...

Create successful ePaper yourself

Delete template?

Save as template?